Immunology and Bi...
Follow
Find
7.0K views | +7 today
 
Immunology and Biotherapies
Page Ressources et Actualités du DIU immunologie et biothérapies
Your new post is loading...
Your new post is loading...
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Resources for DIU Immunologie et Biothérapies

DIU Immunologie et Biotherapies is a french diploma associating many french universities and immunology laboratories. It is dedicated to the involvement of immunology in new biotherapies, either molecular or cellular

Gilbert Faure au nom de l'ASSIM's insight:

We choose Scoop.it as the best curation tool to collect, select, comment informations flowing on the web in this rapidly evolving theme to keep teachers abreast of scientific knowledge and help students surf the wave...

Feel free to be a follower!

 

If you are interested

in Immunology also use http://www.scoop.it/t/immunology

in Mucosal Immunity http://www.scoop.it/t/mucosal-immunity

in Flow Cytometry and Cytomics http://www.scoop.it/t/from-flow-cytometry-to-cytomics

in Allergy an Clinical Immunology http://www.scoop.it/t/allergy-and-clinical-immunology

in Autoimmunity http://www.scoop.it/t/autoimmunity

 

For further informantions on Immune monitoring of Immune therapies, go to

http://www.scoop.it/t/immune-monitoring-1

by MdC

 

Looking for cancer applications inside this topic, use

http://www.scoop.it/t/immunology-and-biotherapies?q=cancer

 

Looking for cytokines and chemokines, use

http://www.scoop.it/t/cytokines-et-chimiokines

 

more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM from Top Selling Monoclonal Antibodies 2014
Scoop.it!

Efficacy and safety of anti–IL-20 monoclonal antibody in patients with rheumatoid arthritis: A randomized phase 2a trial - Šenolt - Arthritis & Rheumatology - Wiley Online Library

Efficacy and safety of anti–IL-20 monoclonal antibody in patients with rheumatoid arthritis: A randomized phase 2a trial - Šenolt - Arthritis & Rheumatology - Wiley Online Library | Immunology and Biotherapies | Scoop.it
Is anti–IL-20 monoclonal antibody useful in patients with Rheumatoid Arthritis? http://t.co/yuf7GVOQjJ #rheum #rheumedu

Via Gilbert Faure au nom de l'ASSIM, Krishan Maggon
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Aridis begins Phase I trial of Aerucin monoclonal antibody to treat acute pneumonia - Drug Development Technology

Aridis begins Phase I trial of Aerucin monoclonal antibody to treat acute pneumonia - Drug Development Technology | Immunology and Biotherapies | Scoop.it
US-based Aridis Pharmaceuticals has started a Phase I clinical trial of Aerucin, the company's fully human IgG1 monoclonal antibody (mAb) against Pseudomonas aeruginosa bacteria, to treat patients with acute pneumonia.Aerucin, which is being...
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

THERADIAG Receives CE Marking for Its 10th Biotherapy Monitoring Test

THERADIAG Receives CE Marking for Its 10th Biotherapy Monitoring Test | Immunology and Biotherapies | Scoop.it
Regulatory News: Theradiag (Paris:ALTER) (ISIN: FR0004197747, Ticker: ALTER), a company specializing in theranostics and in vitro diagnostics, announced today that it has obtained CE marking for its monitoring test of ...
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM from Top Selling Monoclonal Antibodies 2014
Scoop.it!

Philogen :: innovating targeting ::

Philogen :: innovating targeting :: | Immunology and Biotherapies | Scoop.it

Philochem owns five antibody libraries (ETH2-GOLD, PHILO-1, PHILO-2, PHILO-DIAMOND and PHILOtop) that contain over 30 billion different binding specificities.

Philochem’s human antibody libraries (ETH2-GOLD, PHILO-1, PHILO-2 and PHILO-DIAMOND) have been used to generate high-quality binding specificities against >50 different antigens, including human monoclonal antibodies which are currently being developed in clinical trials by Philogen.

 

Philochem’s antibody libraries contain monoclonal antibodies in scFv format. Once monoclonal antibodies which are specific to the target antigen of choice are isolated, they can be easily reformatted into other recombinant antibody formats (e.g., IgG, Fab, mini-antibody, Fc-fusion) using general vectors and well-established procedures which are available at Philochem.


Via Krishan Maggon
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Combination of Targeted and Immuno-therapies For Advanced Melanoma - Immuno-Oncology News

Combination of Targeted and Immuno-therapies For Advanced Melanoma - Immuno-Oncology News | Immunology and Biotherapies | Scoop.it
Here read about the major advancements in treatments with targeted therapy and immunotherapy for advanced melanoma patients.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM from Biotech Pharma Innovation in Oncology, Immunology & beyond.
Scoop.it!

Current ADC Linker Chemistry

Current ADC Linker Chemistry | Immunology and Biotherapies | Scoop.it
The list of ADCs in the clinic continues to grow, bolstered by the success of first two marketed ADCs: ADCETRIS® and Kadcyla®. Currently, there are 40 ADCs in various phases of clinical development. However, only 34 of these have published their structures. Of the 34 disclosed structures, 24 of them use a linkage to the thiol of cysteines on the monoclonal antibody. The remaining 10 candidates utilize chemistry to surface lysines of the antibody. Due to the inherent heterogeneity of conjugation to the multiple lysines or cysteines found in mAbs, significant research efforts are now being directed toward the production of discrete, homogeneous ADC products, via site-specific conjugation. These site-specific conjugations may involve genetic engineering of the mAb to introduce discrete, available cysteines or non-natural amino acids with an orthogonally-reactive functional group handle such as an aldehyde, ketone, azido, or alkynyl tag. These site-specific approaches not only increase the homogeneity of ADCs but also enable novel bio-orthogonal chemistries that utilize reactive moieties other than thiol or amine. This broadens the diversity of linkers that can be utilized which will lead to better linker design in future generations of ADCs.

Via Dominique Blanchard
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM from Cancer Immunotherapy Review
Scoop.it!

Preamble to the 2015 SITC immunotherapy biomarkers taskforce

Preamble to the 2015 SITC immunotherapy biomarkers taskforce | Immunology and Biotherapies | Scoop.it

Abstract


The Society for Immunotherapy of Cancer (SITC) has regularly hosted workshops and working groups focused on immunologic monitoring and immune biomarkers. Due to advances in cancer immunotherapy, including positive results from clinical trials testing new agents and combinations, emerging new technologies for measuring aspects of immunity, and novel candidate biomarkers from early phase trials, the SITC Immune Biomarkers Taskforce has reconvened to review the state of the art, identify current hurdles to further success and to make recommendations to the field. Topics being addressed by individual working groups include: (1) validation of candidate biomarkers, (2) identification of the most promising technologies, (3) testing of high throughput immune signatures and (4) investigation of the pre-treatment tumor microenvironment. Resultant recommendations will be published in JITC.


Via Krishan Maggon
more...
Krishan Maggon 's curator insight, March 25, 2:38 AM
Preamble to the 2015 SITC immunotherapy biomarkers taskforce

Lisa H Butterfield16*, Mary L Disis2, Bernard A Fox3, Samir N Khleif4 and Francesco M Marincola5

*Corresponding author: Lisa H Butterfield butterfieldl@upmc.edu

Author Affiliations

1University of Pittsburgh, Pittsburgh, PA, USA

2University of Washington, Seattle, WA, USA

3Oregon Health and Science University, Portland, OR, USA

4GRU Cancer Center, Georgia Regents University, Augusta, GA, USA

5Sidra Medical and Research Center, Doha, Qatar

6University of Pittsburgh, Hillman Cancer Center, 5117 Centre Avenue, Suite 1.27, Pittsburgh 15213, PA, USA

For all author emails, please log on.

Journal for Immunotherapy of Cancer 2015, 3:8  doi:10.1186/s40425-015-0052-6

The electronic version of this article is the complete one and can be found online at:http://www.immunotherapyofcancer.org/content/3/1/8

Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

The failure of figitumumab: the danger of takin...

The failure of figitumumab: the danger of takin... | Immunology and Biotherapies | Scoop.it
With such a complex and evolving adversary as cancer, it is never a surprise to learn of a negative randomized phase for a novel anti-cancer therapy.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

A novel tetravalent formulation combining the four aggregated domain III-capsid proteins from dengue viruses induces a functional immune response in mice and monkeys

A novel tetravalent formulation combining the four aggregated domain III-capsid proteins from dengue viruses induces a functional immune response in mice and monkeys | Immunology and Biotherapies | Scoop.it
A novel tetravalent formulation combining the four aggregated domain III-capsid proteins from dengue viruses i... http://t.co/q4QnUDWxXI
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM from Top Selling Monoclonal Antibodies 2014
Scoop.it!

Molecular basis for antagonistic activity of anifrolumab, an anti-interferon–α receptor 1 antibody

Molecular basis for antagonistic activity of anifrolumab, an anti-interferon–α receptor 1 antibody | Immunology and Biotherapies | Scoop.it
(2015). Molecular basis for antagonistic activity of anifrolumab, an anti-interferon–α receptor 1 antibody. mAbs: Vol. 7, No. 2, pp. 428-439.

Via Krishan Maggon
more...
Krishan Maggon 's curator insight, March 21, 11:19 AM

Molecular basis for antagonistic activity of anifrolumab, an anti-interferon–α receptor 1 antibody View full textDownload full textOpen accessDOI:10.1080/19420862.2015.1007810Li Penga, Vaheh Oganesyana, Herren Wua, William F Dall’Acquaa& Melissa M Damschrodera*

pages 428-439

Publishing models and article dates explainedReceived: 16 Oct 2014Accepted: 18 Nov 2014Accepted author version posted online: 21 Jan 2015Article Views: 84 Keywordsanifrolumab, MEDI546, IFNAR1, systemic sclerosis, epitope mapping, mutagenesis, enzymatic fragmentation, phage-peptide display, protein docking, Å, ångström, APBS, Adaptive Poisson-Boltzmann Solver, BSA, bovine serum albumin, CDR, complementarity-determining region, CHARMm, Chemistry at HARvard Macromolecular Mechanics, CHO, Chinese hamster ovary, EDTA, ethylene diamine tetra-acetic acid, ELISA, enzyme-linked immunosorbant assay, Fab, fragment antigen-binding, FBS, fetal bovine serum, Fc, fragment crystallizable, IFN, interferon, IFNAR1, interferon alpha receptor 1, IFNAR2, interferon alpha receptor 2, IgG, immunoglobulin, KD, equilibrium dissociation constant, kDa, kilodaltons,L-Cys, L-cysteine, MEMα, minimum essential alpha, MLE, murine lung epithelial, PBS, phosphate buffered saline, PBST, phosphate buffered saline tablets, PCR, polymerase chain reaction, PDB, protein data bank, Ph.D., phage display, PVDF, polyvinylidene difluoride, PyMOL, python-enhanced molecular graphics tool, RDOCK, rigid-body docking algorithm, RU, resonance units, SDS–PAGE, sodium dodecyl sulfate polyacrylamide gel electrophoresis, SPR, surface plasmon resonance, VH, variable heavy, VL, variable light, ZDOCK, rigid-body docking algorithm

Scooped by Gilbert Faure au nom de l'ASSIM from Cancer Immunotherapy Review
Scoop.it!

Macrophages are critical effectors of antibody therapies for cancer

Macrophages are critical effectors of antibody therapies for cancer | Immunology and Biotherapies | Scoop.it
(2015). Macrophages are critical effectors of antibody therapies for cancer. mAbs: Vol. 7, No. 2, pp. 303-310.

Via Krishan Maggon
more...
Krishan Maggon 's curator insight, March 21, 1:50 AM
Macrophages are critical effectors of antibody therapies for cancer View full textDownload full textOpen accessDOI:10.1080/19420862.2015.1011450Kipp Weiskopfabc* & Irving L Weissmanabcd

pages 303-310

Publishing models and article dates explainedReceived: 4 Jan 2015Accepted: 15 Jan 2015Accepted author version posted online: 10 Feb 2015Article Views: 321
Krishan Maggon 's curator insight, March 21, 1:53 AM
Macrophages are critical effectors of antibody therapies for cancer View full textDownload full textOpen accessDOI:10.1080/19420862.2015.1011450Kipp Weiskopfabc* & Irving L Weissmanabcd

pages 303-310

Publishing models and article dates explainedReceived: 4 Jan 2015Accepted: 15 Jan 2015Accepted author version posted online: 10 Feb 2015Article Views: 321
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Results of Bococizumab, A Monoclonal Antibody Against Proprotein Co... - PubMed - NCBI

Am J Cardiol. 2015 Feb 12. pii: S0002-9149(15)00695-5. doi: 10.1016/j.amjcard.2015.02.006. [Epub ahead of print]
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by CFDA - ChineseBrains

Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by CFDA - ChineseBrains | Immunology and Biotherapies | Scoop.it
Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody http://t.co/waEBUPwojw #accepted #antibody #application #cfda
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

ImmunID sur Twitter

ImmunID sur Twitter | Immunology and Biotherapies | Scoop.it
Very nice & interesting discussion on #Immunology #immunotherapy, #precisionmedicine. Thanks @NCBES for invitation! pic.twitter.com/C2no1T3LeC
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

THERADIAG receives CE marking for its 10th biotherapy monitoring test « Theradiag

THERADIAG receives CE marking for its 10th biotherapy monitoring test « Theradiag | Immunology and Biotherapies | Scoop.it
Theradiag: CE Marking for Its 10th Biotherapy Monitoring Test http://t.co/cGUoGNGmNs More French biotech firms at http://t.co/ZzKCZdtV0x
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM from Alzheimer's Disease R&D Review
Scoop.it!

Neurimmune - RTM™ Technology Platform

Neurimmune - RTM™ Technology Platform | Immunology and Biotherapies | Scoop.it

Reverse Translational Medicine™ (RTM™) is Neurimmune’s proprietary technology platform. It is based on the scientific understanding and high-throughput analyses of human immune responses to disease-related proteins in selected populations including elderly with the capability to stay healthy during the aging process.

 

Neurimmune’s recombinant human monoclonal antibody therapeutics combine the full complement of advantages provided by human affinity maturation and tolerance selection. These processes are biologically optimized through evolutionary processes over millions of years providing unsurpassed efficacy and safety in human subjects.

 

Neurimmune’s molecular engineering technology preserves favorable immunobiological features of human-derived antibodies creating an entirely novel generation of highly optimized biopharmaceutical drugs.

With their superior biophysical, pharmacological and safety properties,

 

Neurimmune’s therapeutic antibodies combine first-in-class with best-in-class potential. As a result, they provide considerable advantages over competing products generated by conventional target-to-lead development cycles commonly applied by the biopharmaceutical industry. 


Via Krishan Maggon
more...
Krishan Maggon 's curator insight, March 22, 12:22 PM

Neurimmune aims at the development of disease-modifying treatments for Alzheimer’s disease, and partnered its first RTMTM-derived antibody program Aducanumab (BIIB037) with Biogen Idec in 2007. Aducanumab (BIIB037) is a recombinant human monoclonal antibody targeting Abeta aggregates that are thought to play a role in the neurodegenerative process in Alzheimer’s disease. Aducanumab (BIIB037) is currently being investigated in a Phase 1b study (PRIME) in patients with prodromal and mild Alzheimer’s disease. The interim analysis showed a dose-dependent, time-dependent, and statistically significant reduction of beta-amyloid from the brain along with an effect on cognition in patients with prodromal or mild Alzheimer's disease.

 

In 2010, Neurimmune also partnered its second AD program NI-105 on recombinant human monoclonal antibodies targeting tau with Biogen Idec.

Krishan Maggon 's curator insight, March 22, 12:24 PM

Neurimmune aims at the development of disease-modifying treatments for Alzheimer’s disease, and partnered its first RTMTM-derived antibody program Aducanumab (BIIB037) with Biogen Idec in 2007. Aducanumab (BIIB037) is a recombinant human monoclonal antibody targeting Abeta aggregates that are thought to play a role in the neurodegenerative process in Alzheimer’s disease. Aducanumab (BIIB037) is currently being investigated in a Phase 1b study (PRIME) in patients with prodromal and mild Alzheimer’s disease. The interim analysis showed a dose-dependent, time-dependent, and statistically significant reduction of beta-amyloid from the brain along with an effect on cognition in patients with prodromal or mild Alzheimer's disease.

 

In 2010, Neurimmune also partnered its second AD program NI-105 on recombinant human monoclonal antibodies targeting tau with Biogen Idec.

Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Peter Johnson sur Twitter

Peter Johnson sur Twitter | Immunology and Biotherapies | Scoop.it
In Munich for ITOC2: excitement about checkpoint antibodies, T cell therapy, small molecule immunomodulators.. pic.twitter.com/fOtXZ8yera
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Broad Blockade Antibody Responses in Human Volunteers after Immunization with a Multivalent Norovirus VLP Candidate Vaccine: Immunological Analyses from a Phase I Clinical Trial

Broad Blockade Antibody Responses in Human Volunteers after Immunization with a Multivalent Norovirus VLP Candidate Vaccine: Immunological Analyses from a Phase I Clinical Trial | Immunology and Biotherapies | Scoop.it
Lisa Lindesmith and colleagues assess the potential of a candidate virus-like particle (VLP) vaccine to induce antibody responses to antigenically divergent norovirus strains.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM from Top Selling Monoclonal Antibodies 2014
Scoop.it!

Antibody therapies and their challenges in the treatment of age-related macular degeneration

Abstract

Age-related macular degeneration (AMD) is the leading cause of vision loss in the western world. This multifactorial disease results from the combined contributions of age, environment and genetic predisposition. Antibody-based treatment of late-stage neovascular AMD with inhibitors of vascular endothelial growth factor has had great success, which is now the goal for currently untreatable AMD manifestations. The existence of an immune-privileged environment in the eye supports the feasibility of localized antibody therapy. Many different antibodies against various targets are being developed for the treatment of AMD, which reflects the etiological complexity of the disease. This review provides an overview of 19 potential therapeutic antibodies targeting angiogenesis, the complement system, inflammation or amyloid beta deposition in the eye. It summarizes the immunoglobulin structure, the specific target and study outcomes for each approach. The latter include beneficial results or adverse effects in AMD models and patients. Finally, this article discusses the challenges in the development of antibody-based drugs to treat degenerative processes in the posterior eye. In spite of these difficulties, to date, the following four antibodies have overcome the technical and preclinical hurdles and are being tested in active clinical studies: Lampalizumab, Sonepcizumab, GSK933776 and LFG316. We conclude that, while there are some antibody-based drugs that have made it into clinical practice, a successful transfer from bench to beside is still pending for many promising approaches.

 


Via Krishan Maggon
Gilbert Faure au nom de l'ASSIM's insight:
Nineteen antibodies in the development for AMD treatment are described. • Antibody targets are: angiogenesis, complement, inflammation or amyloid β. • Antibody therapy faces known challenges of chemical drugs. • Antibody structure, specificity and effector function offer new possibilities. • An anti-AMD “toolbox” is more likely for dry AMD therapy than a “magic bullet”.
more...
Krishan Maggon 's curator insight, March 23, 4:36 AM

Highlights

 

Nineteen antibodies in the development for AMD treatment are described.

Antibody targets are: angiogenesis, complement, inflammation or amyloid β.

Antibody therapy faces known challenges of chemical drugs.

Antibody structure, specificity and effector function offer new possibilities.

An anti-AMD “toolbox” is more likely for dry AMD therapy than a “magic bullet”.

Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

CAR-Modified T Cell Therapy in ALL - OncLive

CAR-Modified T Cell Therapy in ALL - OncLive | Immunology and Biotherapies | Scoop.it
CAR-Modified T Cell Therapy in ALL OncLive Chimeric antigen receptor (CAR) T cell therapies are engineered through the genetic modification of an individual's T cells to express a synthetic receptor that recognizes a particular antigen or protein,...
more...
Dominique Blanchard's curator insight, March 25, 5:09 AM

In ALL 80% response rate but 50% of patient in intensive care unit. 

Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Accelerating Identification and Regulatory Approval of Investigational Cancer Drugs

Accelerating Identification and Regulatory Approval of Investigational Cancer Drugs | Immunology and Biotherapies | Scoop.it
The development of new drugs is becoming increasingly expensive—and oncology drugs, in particular, have a high clinical failure rate.1,2 The current return on capital investment in drug development by US public companies was recently reported as...
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

TxCell - antigen-specific Type 1 Treg cells - Biotech 365

TxCell - antigen-specific Type 1 Treg cells - Biotech 365 | Immunology and Biotherapies | Scoop.it
TxCell - antigen-specific Type 1 Treg cells. TxCell is developing personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) .
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Transmission of psoriasis by allogeneic bone marrow transplantation and blood ... - Nature.com

Transmission of psoriasis by allogeneic bone marrow transplantation and blood ... - Nature.com | Immunology and Biotherapies | Scoop.it
Blood Cancer Journal is a peer-reviewed, open access online journal publishing pre-clinical and clinical work in the field of hematology with ramifications into translational biology research down to new therapies...
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Veterinary Research | Full text | Monoclonal antibody specific to HA2 glycopeptide protects mice from H3N2 influenza virus infection

Canine influenza virus (CIV) subtype H3N2 is a newly identified, highly contagious respiratory pathogen that causes cough, pneumonia and other respiratory symptoms in dogs.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Developing in vitro expanded CD45RA+ regulatory T cells as an adoptive cell therapy for Crohn's disease -- Canavan et al. -- Gut

Developing in vitro expanded CD45RA+ regulatory T cells as an adoptive cell therapy for Crohn's... http://t.co/J6mktDIdX4
more...
No comment yet.